# OnCo record paper-keynote-564-nejm-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-564-nejm-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-564-nejm-2021" ;
  schema:name "KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery"@en ;
  schema:description "One year of pembrolizumab after surgery for high-risk kidney cancer reduced relapses by about a third and, in later follow-up, became the first adjuvant treatment to help kidney cancer patients live longer."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-564-nejm-2021/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2106391>, <https://doi.org/10.1056/NEJMoa2312695>, <https://clinicaltrials.gov/study/NCT03142334> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2106391> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Choueiri TK, Tomczak P, Park SH, et al." ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:institutions <https://onco.cc/institutions/dana-farber/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/irae/> ;
  onco:people <https://onco.cc/people/toni-choueiri/>, <https://onco.cc/people/lee-jae-lyun/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-negative-results/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:journals <https://onco.cc/journals/nejm/> .